JNJ-<wbr/>26481585 (hydro<wbr/>chloride)

JNJ-26481585 (hydrochloride)

CAT N°: 14088
Price:

From 122.00 103.70

JNJ-26481585 is a histone deacetylase (HDAC) inhibitor.{32219} It inhibits class I (IC50s = 0.11, 0.33, 4.86, and 4.26 nM for HDAC1, -2, -3, and -8, respectively), class IIa (IC50s = 0.64, 3.69, 119, and 32.1 nM for HDAC4, -5, 7-, and -9, respectively), and class IIb HDACs (IC50s = 76.8 and 0.46 nM for HDAC6 and HDAC10, respectively), as well as HDAC11 (IC50 = 0.37 nM), the class IV HDAC. JNJ-26481585 (200 nM) induces apoptosis, pyroptosis, and ferroptosis in CAL-27 and Tca8113 tongue squamous cell carcinoma cells.{57471} It also induces histone H3 acetylation in tumor tissue in vivo and completely inhibits tumor growth in HCT116 Ras mutant and C170HM2 mouse xenograft models when administered at a dose of 10 mg/kg once per day.{32219}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-hydroxy-2-[4-[[[(1-methyl-1H-indol-3-yl)methyl]amino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide, dihydrochloride
  • Correlated keywords
    • JNJ26481585 hydroxamate histone deacetylase HDAC3 HDAC2 HDAC8 apoptosis Ras HCT116 cycle-arrest HDAC5 HDAC7 HDAC9 CAL27 Tca 8113 C170HM 875320-29-9
  • Product Overview:
    JNJ-26481585 is a histone deacetylase (HDAC) inhibitor.{32219} It inhibits class I (IC50s = 0.11, 0.33, 4.86, and 4.26 nM for HDAC1, -2, -3, and -8, respectively), class IIa (IC50s = 0.64, 3.69, 119, and 32.1 nM for HDAC4, -5, 7-, and -9, respectively), and class IIb HDACs (IC50s = 76.8 and 0.46 nM for HDAC6 and HDAC10, respectively), as well as HDAC11 (IC50 = 0.37 nM), the class IV HDAC. JNJ-26481585 (200 nM) induces apoptosis, pyroptosis, and ferroptosis in CAL-27 and Tca8113 tongue squamous cell carcinoma cells.{57471} It also induces histone H3 acetylation in tumor tissue in vivo and completely inhibits tumor growth in HCT116 Ras mutant and C170HM2 mouse xenograft models when administered at a dose of 10 mg/kg once per day.{32219}

We also advise you